Volition, a multi-national epigenetics company, will host a virtual investor event on February 14, 2025.
Dr. Retter will focus on Nu.Q® NETs H 3.1, a novel biomarker for early mortality and organ function in sepsis, and an independent predictor of the need for RRT.
Volition's progress to commercialization through both licensing and direct and indirect sales will be provided by Mr. Forterre.
There will be a live question and answer session.
About Dr. Andrew Retter.
Andrew Retter is the Clinical Lead for Critical Care at one of the UK's largest hospitals in London.
About Gael Forterre.
He is focused on building a strong commercialization plan and team to drive the extensive range of products developed using the Nu.Q® platform.
After graduating from Sorbonne Paris I with a master's in finance, Gael went on to work in investment banking and executive roles for over fifteen years.
About Volition.
Volition is dedicated to saving lives and improving outcomes for people and animals with life-threatening diseases through earlier detection, as well as disease and treatment monitoring.
Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis.
Volition has an innovation laboratory and office in the U.S. and London.
The contents found at Volition's website address are not included in this document.
Louise Batchelor, Volition, can be contacted by email.
Jeremy Feffer is the investor relations person for LifeSci Advisors.
SOURCE VolitionRx.
Volition, a multi-national epigenetics company, today announced the results of a large-scale study.
The Business Review of 2024 was issued by Volition, a multi-national epigenetics company.
Do not sell or share my information.

Source prnewswire